The "Global Markets for Drug-Device Combinations" report has been added to ResearchAndMarkets.com's offering. This report highlights drug-device combinations' current and future market potential and a ...
SYNC-T, an investigational therapy that combines a device-induced vaccination at the tumor site with intratumoral infusion of a multitarget biologic drug led to numerous clinical responses in patients ...
The "Drug Device Combination Products Market by Type (Injectable, Transdermal Patch, Infusion Pump, Drug-eluting Stent, Inhaler), Application (Diabetes, Oncology, Pain, Opthalmology), End User ...
Subsequent approvals of embedded drug-device pharmaceuticals, at least those from Proteus, will be able to benefit from the precedent set here. "It’s obviously very important, we think, to the future ...
MIT researcher Michael Cima says by combining drug therapy with medical devices, manufacturers can see greater payoffs, according to a Mass Device report. The drug-device combination becomes a ...
ND0612 is an investigational drug-device therapy that provides a 24-hour continuous subcutaneous infusion of levodopa/carbidopa solution. The Food and Drug Administration (FDA) has accepted for review ...
The global drug device combination products market is forecasted to grow at a 7.9 percent compound annual growth rate, reaching $115.1 billion by 2019, according to a news release. In 2012, the market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results